Cargando…

MicroRNA-20a-5p Downregulation by Atorvastatin: A Potential Mechanism Involved in Lipid-Lowering Therapy

The treatment of hypercholesterolemia is mainly based on statins. However, the response to pharmacological therapy shows high inter-individual variability, resulting in variable effects in both lipid lowering and risk reduction. Thus, a better understanding of the lipid-lowering mechanisms and respo...

Descripción completa

Detalles Bibliográficos
Autores principales: Saavedra, Kathleen, Leal, Karla, Saavedra, Nicolás, Prado, Yalena, Paez, Isis, Ubilla, Carmen G., Rojas, Gabriel, Salazar, Luis A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9104095/
https://www.ncbi.nlm.nih.gov/pubmed/35563413
http://dx.doi.org/10.3390/ijms23095022
_version_ 1784707710970757120
author Saavedra, Kathleen
Leal, Karla
Saavedra, Nicolás
Prado, Yalena
Paez, Isis
Ubilla, Carmen G.
Rojas, Gabriel
Salazar, Luis A.
author_facet Saavedra, Kathleen
Leal, Karla
Saavedra, Nicolás
Prado, Yalena
Paez, Isis
Ubilla, Carmen G.
Rojas, Gabriel
Salazar, Luis A.
author_sort Saavedra, Kathleen
collection PubMed
description The treatment of hypercholesterolemia is mainly based on statins. However, the response to pharmacological therapy shows high inter-individual variability, resulting in variable effects in both lipid lowering and risk reduction. Thus, a better understanding of the lipid-lowering mechanisms and response variability at the molecular level is required. Previously, we demonstrated a deregulation of the microRNA expression profile in HepG2 cells treated for 24 h with atorvastatin, using a microarray platform. In the present study, we evaluated the expression of hsa-miR-17-5p, hsa-miR-20a-5p and hsa-miR-106a-5p in hypercholesterolemic patients before and after atorvastatin treatment and in HepG2 cells treated for 24 h with atorvastatin The miRNA hsa-mir-20a-5p was repressed after atorvastatin treatment in hypercholesteremic subjects and in HepG2 cells in culture. Repression of hsa-mir-20a-5p increased LDLR gene and protein expression in HepG2 cells, while hsa-mir-20a-5p overexpression reduced LDLR gene and protein expression.
format Online
Article
Text
id pubmed-9104095
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-91040952022-05-14 MicroRNA-20a-5p Downregulation by Atorvastatin: A Potential Mechanism Involved in Lipid-Lowering Therapy Saavedra, Kathleen Leal, Karla Saavedra, Nicolás Prado, Yalena Paez, Isis Ubilla, Carmen G. Rojas, Gabriel Salazar, Luis A. Int J Mol Sci Article The treatment of hypercholesterolemia is mainly based on statins. However, the response to pharmacological therapy shows high inter-individual variability, resulting in variable effects in both lipid lowering and risk reduction. Thus, a better understanding of the lipid-lowering mechanisms and response variability at the molecular level is required. Previously, we demonstrated a deregulation of the microRNA expression profile in HepG2 cells treated for 24 h with atorvastatin, using a microarray platform. In the present study, we evaluated the expression of hsa-miR-17-5p, hsa-miR-20a-5p and hsa-miR-106a-5p in hypercholesterolemic patients before and after atorvastatin treatment and in HepG2 cells treated for 24 h with atorvastatin The miRNA hsa-mir-20a-5p was repressed after atorvastatin treatment in hypercholesteremic subjects and in HepG2 cells in culture. Repression of hsa-mir-20a-5p increased LDLR gene and protein expression in HepG2 cells, while hsa-mir-20a-5p overexpression reduced LDLR gene and protein expression. MDPI 2022-04-30 /pmc/articles/PMC9104095/ /pubmed/35563413 http://dx.doi.org/10.3390/ijms23095022 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Saavedra, Kathleen
Leal, Karla
Saavedra, Nicolás
Prado, Yalena
Paez, Isis
Ubilla, Carmen G.
Rojas, Gabriel
Salazar, Luis A.
MicroRNA-20a-5p Downregulation by Atorvastatin: A Potential Mechanism Involved in Lipid-Lowering Therapy
title MicroRNA-20a-5p Downregulation by Atorvastatin: A Potential Mechanism Involved in Lipid-Lowering Therapy
title_full MicroRNA-20a-5p Downregulation by Atorvastatin: A Potential Mechanism Involved in Lipid-Lowering Therapy
title_fullStr MicroRNA-20a-5p Downregulation by Atorvastatin: A Potential Mechanism Involved in Lipid-Lowering Therapy
title_full_unstemmed MicroRNA-20a-5p Downregulation by Atorvastatin: A Potential Mechanism Involved in Lipid-Lowering Therapy
title_short MicroRNA-20a-5p Downregulation by Atorvastatin: A Potential Mechanism Involved in Lipid-Lowering Therapy
title_sort microrna-20a-5p downregulation by atorvastatin: a potential mechanism involved in lipid-lowering therapy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9104095/
https://www.ncbi.nlm.nih.gov/pubmed/35563413
http://dx.doi.org/10.3390/ijms23095022
work_keys_str_mv AT saavedrakathleen microrna20a5pdownregulationbyatorvastatinapotentialmechanisminvolvedinlipidloweringtherapy
AT lealkarla microrna20a5pdownregulationbyatorvastatinapotentialmechanisminvolvedinlipidloweringtherapy
AT saavedranicolas microrna20a5pdownregulationbyatorvastatinapotentialmechanisminvolvedinlipidloweringtherapy
AT pradoyalena microrna20a5pdownregulationbyatorvastatinapotentialmechanisminvolvedinlipidloweringtherapy
AT paezisis microrna20a5pdownregulationbyatorvastatinapotentialmechanisminvolvedinlipidloweringtherapy
AT ubillacarmeng microrna20a5pdownregulationbyatorvastatinapotentialmechanisminvolvedinlipidloweringtherapy
AT rojasgabriel microrna20a5pdownregulationbyatorvastatinapotentialmechanisminvolvedinlipidloweringtherapy
AT salazarluisa microrna20a5pdownregulationbyatorvastatinapotentialmechanisminvolvedinlipidloweringtherapy